Doutorado em Ciência Animal (EVZ)
URI Permanente para esta coleção
Navegar
Navegando Doutorado em Ciência Animal (EVZ) por Por Orientador "Carvalho, Rosângela de Oliveira Alves"
Agora exibindo 1 - 2 de 2
Resultados por página
Opções de Ordenação
Item Ação do LASSBio 294 sobre os parâmetros cardiovasculares em modelo experimental de cardiomiopatia dilatada em coelhos(Universidade Federal de Goiás, 2016-12-16) Costa, Ana Paula Araújo; Moura, Veridiana Maria Brianezi Dignani de; http://lattes.cnpq.br/8773201078957745; Oliveira, Valéria de; Carvalho, Rosângela de Oliveira Alves; http://lattes.cnpq.br/5593911382353878; Carvalho, Rosângela de Oliveira Alves; Passos, Andréa Cintra Bastos Tôrres; Tárraga, Kátia Mitsube; Lima, Aline Maria Vasconcelos; Araújo , Eugênio Golçalves deDilated cardiomyopathy (DCM) is a disease of the heart muscle that culminates in dilatation of the left ventricle, or both, and myocardial contractile dysfunction. The clinical phase of the disease is characterized by congestive heart failure signs (CHF), with or without arrhythmias. The treatment involves the use of drugs aimed at reducing the signs of CHF and arrhythmias, with diuretics, positive inotropic, vasodilator and antiarrhythmic. A new drug candidate (LASSBio 294), capable of promoting combined positive inotropic and vasodilating effects, has recently been developed, and have been tested in pre-clinical study in healthy Beagle dogs with promising results. Therefore, this study proposed to verify the action of the drug prototype LASSBio 294, at a dose of 2mg/Kg on cardiovascular parameters of rabbits with DCM experimentally induced by doxorubicin, using as positive control the pimobendan at a dose of 0.3mg/kg. The DCM was induced by intravenous administration of 1 mg/kg of doxorubicin, at a concentration of 2mg/ml, twice a week, for three weeks, and then weekly until it reached fractional shortening less or equal to 25%. As methods of evaluating the LASSBio 294 action on the cardiovascular system of rabbits and monitor the induction of DMC, the following tests were performed: electrocardiography, echodopplercardiography, measurement of blood pressure, chest radiograph, dosage of cardiac lesions, and kidney and liver function biomarkers and hematologic evaluation. At the end of the induction protocol the animals were randomly divided into two groups A (LASSBio 294) and B (pimobendan) and underwent treatment for 30 days, twice a day. At the end of the study it was concluded that the DCM model induced by doxorubicin is a good model to study the disease and its consequences, leading to systolic and diastolic dysfunction with dilatation of the left ventricle. However the time for induction of DCM is inaccurate and the occurrence of multisystemic toxicity, such as nephrotoxicity and myelosuppression, contributes to high mortality rate in this model (35%). It can be concluded that LASSBio 294 is effective in increasing systolic function, improving diastolic function, without altering rabbits blood pressure, has no pro-arrhythmogenic or toxic effect, and reduced the serum creatinine concentration of the animals, but it does not prevent the evolution of the congestive condition.Item Ácidos graxos ômega 3 na dieta de cães com doença valvar mitral(Universidade Federal de Goiás, 2018-02-23) Nasciutti, Priscilla Regina; Borges, Naida Cristina; http://lattes.cnpq.br/9181279951885005; Martins, Danieli Brolo; http://lattes.cnpq.br/2159963349521553; Carvalho, Rosângela de Oliveira Alves; http://lattes.cnpq.br/5593911382353878; Carvalho, Rosângela de Oliveira Alves; Pereira Neto, Gláucia Bueno; Passos, Andréa Cintra Bastos Torres; Damasceno, Adilson Donizeti; Lima, Aline Maria VasconcelosMitral valve disease (MVD) is characterized by thickening in the valvular leaflets and may lead to heart failure. Pharmacological treatment of the disease with vasodilators, positive inotropes and diuretics is used in conjunction with dietary management. Omega 3 (ω-3) supplementation has been associated with modulation of blood pressure (BP) and heart rate, improvement of Doppler echocardiography, antiarrhythmic, anti-inflammatory and antidysiphyde effects. In the absence of prospective clinical studies, the objective was to evaluate the influence of ω-3 supplementation in dogs with MVD. For this purpose, 41 dogs were followed up every three months for 12 months by means of clinical evaluation, BP measurement, electrocardiography, Doppler echocardiography, chest radiography, laboratory tests, dosages of inflammatory mediators and cardiac biomarker. The dogs were classified in stages B1, B2 and C, according to the ACVIM consensus. Dogs were randomly divided into the ω-3 group, which received food for dogs with heart diseases supplemented with ω-3 and control group (even food without supplementation). In stage B1 only dogs from the ω-3 group were evaluated. At the end of 12 months, no changes were observed in the parameters evaluated. In dogs stage B2 and C, there was an increase in the serum levels of inflammatory mediators, in a larger amplitude in the control group. The ω-3 preserved body condition score, muscle condition score and reduced by 2.96 times the chance of developing arrhythmias. The DIVEdN and VHS measurements were higher in the control group and correlated with NTproBNP cardiac biomarker concentrations. It is concluded that the supplementation with ω-3 in patients in classes B2 and C, maintains the body condition, helps reduce volume overload, has an antiarrhythmic effect and keeps dogs with MVD in the firsts stages of the disease.